Campbell & Co Investment Adviser’s Intellia Therapeutics NTLA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,319	Closed	-$497K	–	1309
2025 Q4	$497K	Buy	+55,319	New	+$762K	0.02%	829
2025 Q2	–	Sell	-28,302	Closed	-$201K	–	1359
2025 Q1	$201K	Buy	+28,302	New	+$286K	0.02%	942
2023 Q1	–	Sell	-14,768	Closed	-$515K	–	964
2022 Q4	$515K	Buy	+14,768	New	+$702K	0.12%	297
2022 Q3	–	Sell	-6,822	Closed	-$353K	–	855
2022 Q2	$353K	Buy	6,822 +2,959	+77%	+$150K	0.1%	400
2022 Q1	$281K	Buy	+3,863	New	+$327K	0.08%	502

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Campbell & Co Investment Adviser's NTLA Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 55,319 shares — an estimated $497K sold.

Campbell & Co Investment Adviser first reported a position in NTLA in Q1 2022 and held it in 5 quarters. The position peaked at $515K in Q4 2022. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 55,319 Intellia Therapeutics shares in Q1 2026, an estimated $497K.
Campbell & Co Investment Adviser first reported a position in Intellia Therapeutics in Q1 2022 and held it in 5 quarters.
Campbell & Co Investment Adviser's Intellia Therapeutics position peaked at $515K in Q4 2022.
304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.